After a year-long takeover battle for the owner of France’s best-selling painkiller, Sanofi’s decision to sell its ...

US private equity firm Clayton Dubilier & Rice thought it had a deal to buy Sanofi’s consumer business. Losing bidder PAI ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

Christopher is also a Sanofi board member and a member of the Strategy Committee. Since April 2011, he has also been the Chairman of Genzyme. In 2011, net sales reached €33,389 million ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

Alphina Therapeutics, a biotechnology company developing a best-in-class NAMPT inhibitor for the treatment of a range of ...

The Fortune 500 Europe has a feeble share of tech companies. But its industrial giants are increasingly turning to generative ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

Iulia Ionescu – General Manager at Sanofi states: “It was a pleasure to moderate ... stated Delia Necula – President of ...

France will take a stake in Sanofi's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on ...

Sanofi is now in “exclusive negotiations ... which will buy up a 2% stake in Opella and take over a seat on its board under the current plan. With the proposed transaction, which could ...